GGrantIndex
← Leaderboards

New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc

New York, NY

Compare ↔
$1,025,750,969
Total funding
686
Grants

Funding over time

peak $82.6M · FY2006–25
$100M$75M$50M$25M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$1,014,372,041 · 674
CDC$20,536,801 · 12
AHRQ$894,755 · 1
SAMHSA$0 · 2

By mechanism

R01$582,347,559 · 263
P50$72,703,252 · 56
R21$42,687,200 · 104
U01$40,838,200 · 20
P30$39,494,409 · 34
UH3$33,953,315 · 3

Investigators at New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Corianna Sichel$740,2501 gr2Genevra Jones$689,7671 gr3Raymond Balise$654,5121 gr4Milenna Tamara Van Dijk$498,0001 gr5Clay Orion Lacefield$489,1971 gr6Ofir Livne$372,4381 gr7Yaara Zisman-Ilani$249,6571 gr8David Stanley Fink$248,7911 gr

Emerging Leaders

6–10 yrs in

1David Pagliaccio$3,785,0783 gr2Alexander Harris$3,670,6433 gr3Claudia I Lugo-Candelas$2,883,0862 gr4Arthur R Williams$2,625,9584 gr5Iruma Bello$2,512,2581 gr6George Jose Musa$2,382,4112 gr7Francesca Zanderigo$2,301,5602 gr8Philip Kreniske$1,997,4403 gr

All-Time

Most funded here, all years

1Joseph J Mann$25,265,96213 gr2Alan Stewart Brown$18,584,1438 gr3Martin Picard$16,657,18011 gr4Claude Ann Mellins$16,092,9424 gr5Rene Hen$15,161,1979 gr6Maura Boldrini$14,818,7808 gr7Bret R Rutherford$13,523,4987 gr8Christine Delorenzo$13,363,7746 gr

Largest grants

New Experimental Medicine Studies: Fast-Fail Trials in Psychotic Spectrum$4,479,063
N01 · FY2015 · MH
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components$4,121,081
UG3 · FY2018 · DA
Evaluation of safety and pharmacokinetics of naltrexone implant$4,109,018
UH3 · FY2021 · DA
Evaluation of safety and pharmacokinetics of naltrexone implant$4,087,023
UH3 · FY2022 · DA
Evaluation of safety and pharmacokinetics of naltrexone implant$3,864,542
UH3 · FY2023 · DA
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components$3,788,472
UG3 · FY2019 · DA
Evaluation of safety and pharmacokinetics of naltrexone implant$3,713,497
UG3 · FY2019 · DA
Breaking the cycle of intergenerational disadvantage: neurodevelopment among Puerto Rican children.$3,608,049
UH3 · FY2021 · OD
Breaking the cycle of intergenerational disadvantage: neurodevelopment among Puerto Rican children.$3,608,049
UH3 · FY2020 · OD
Breaking the cycle of intergenerational disadvantage: neurodevelopment among Puerto Rican children.$3,607,992
UH3 · FY2022 · OD
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components$3,569,552
UH3 · FY2023 · DA
Novel Medication Approaches for Substance Abuse$3,545,749
P50 · FY2010 · DA
Novel Medication Approaches for Substance Abuse$3,506,337
P50 · FY2011 · DA
Novel Medication Approaches for Substance Abuse$3,440,132
P50 · FY2012 · DA
Breaking the cycle of intergenerational disadvantage: neurodevelopment among Puerto Rican children.$3,407,813
UH3 · FY2019 · OD
Parent-child transmission of trauma in a longitudinal cohort: impact on aging-related mental and physical health well-being$3,355,744
RF1 · FY2025 · AG
Phase 1 and 2 studies of sublingual dexmedetomidine, an alpha 2 adrenergic agonist, for treating opioid withdrawal$3,312,204
UG3 · FY2022 · DA
Novel Medication Approaches for Substance Abuse$3,250,717
P50 · FY2013 · DA
Breaking the cycle of intergenerational disadvantage: neurodevelopment among Puerto Rican children.$3,057,549
UH3 · FY2018 · OD
Evaluation of safety and pharmacokinetics of naltrexone implant$3,010,138
UG3 · FY2018 · DA